Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents Authors
First Online: 16 April 2013 DOI:
Cite this article as: Caccia, S. Pediatr Drugs (2013) 15: 217. doi:10.1007/s40272-013-0024-6 Abstract
Pediatric behavioral and affective disorders often require antipsychotic therapy, in combination with psychotherapeutic interventions, for their treatment and stabilization. Although pharmacotherapy can include either typical or atypical antipsychotics, the latter are generally preferred because of their apparently lower risk of adverse effects. Recent controlled trials have demonstrated the efficacy of some of these agents (including aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) in adolescent schizophrenia and children or adolescent bipolar mania, or to treat severe aggression and self-injury in the context of autism in children and adolescents. Although few studies have systematically monitored their short- and, more importantly, long-term safety, current evidence indicates that sedation, hyperprolactinemia, and metabolic abnormalities such as excess weight gain, diabetes, and related cardiovascular effects were clinically relevant adverse effects in young patients, with the individual agents differing in their propensity to induce these effects. When prescribing antipsychotics for children and adolescents, physicians should therefore be aware of the specific adverse effect profiles and patients should be closely monitored for the short- and long-term development of adverse events. In pediatric patients, the starting dose, titration plan, and maintenance dose of antipsychotics must be based on their pharmacokinetics and metabolism, as in adults. Because there are significant individual differences in drug and active metabolite(s) pharmacokinetics and metabolism, which may be further affected by a number of confounding factors (including demographic variables, phenotype and drug interactions), therapeutic drug monitoring may be a valid tool for individualizing dosage, but its interpretation should also take account of changes in pharmacodynamic sensitivity with the development during childhood and adolescence.
Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(7):29–40.
Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy tolerability and differential sensitivity to extrapyramidal symptoms. J Neural Transm Suppl. 2005;69:121–41.
Kapetanovic S, Simpson GM. Review of antipsychotics in children and adolescents. Expert Opin Pharmacother. 2006;7:1871–85.
Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71(2):179–208.
Gentile S. Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders. Paediatr Drugs. 2011;13(5):291–302.
McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clin Psychol Rev. 2011;31(3):465–71.
Thomas T, Stansifer L, Findling RL. Psychopharmacology of pediatric bipolar disorders in children and adolescents. Pediatr Clin North Am. 2011;58(1):173–87.
Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2009;18(3):250–60.
Newcomer J. Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93.
Hong IS, Bishop JR. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother. 2010;44(7–8):1171–80.
De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–58.
Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651–68.
Caccia S, Clavenna A, Bonati M. Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol. 2011;7(5):591–608.
Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629–35.
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–87.
Kahn RS, Fleischhacker WW, Boter H, EUFEST Study Group, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–97.
Lieberman JA, Stroup TS, McEvoy JP, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.
Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–31.
Remschmidt H, Fleischhaker C, Hennighausen K, et al. Management of schizophrenia in children and adolescents: the role of clozapine. Pediatric Drugs. 2000;10:253–62.
Kranzler HN, Kester HM, Gerbino-Rosen G, et al. Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions. Child Adolesc Psychiatr Clin N Am. 2006;15(1):135–59.
Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53:1090–7.
Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63:721–30.
Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63(5):524–9.
Cianchetti C, Ledda MG. Effectiveness and safety of antipsychotics in early onset psychoses: a long-term comparison. Psychiatry Res. 2011;189(3):349–56.
Kant R, Chalansani R, Chengappa KN, et al. The off-label use of clozapine in adolescents with bipolar disorder intermittent explosive disorder or posttraumatic stress disorder. J Child Adolesc Psychopharmacol. 2004;14(1):57–63.
Gerbino-Rosen G, Roofeh D, Tompkins DA, Feryo D, et al. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005;44(10):1024–31.
Kennedy E, Kumar A, Datta S. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev 2007;(3):CD004027.
Gogtay N, Rapoport J. Clozapine use in children and adolescent. Expert Opin Pharmacother. 2008;9(3):459–65.
Mehler-Wex C, Kölch M, Kirchheiner J, et al. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health. 2009;3:14.
Singh MK, Ketterm TA, Chang KD. Atypical antipsychotics for acute manic and mixed episodes in children and adolescents with bipolar disorder: efficacy and tolerability. Drugs. 2010;70(4):433–42.
Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007;9(5):343–54.
Pediatric Efficacy and Safety Trial (R076477-PSZ-3001): a randomized multicenter double-blind weight-based fixed-dose (paliperidone ER Low Medium and High group) placebo-controlled trial of the efficacy and safety of paliperidone ER for the treatment of schizophrenia in adolescent subjects aged 12 to 17 years.
NCT00796081 (PK paliperidone).
Nussbaumm A, Stroup TS. Paliperidone for schizophrenia. Cochrane Database Syst Rev 2008;(2):CD006369.
Gahrm M, Köllem MA, Schönfeldt-Lecuonam C, et al. Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug Des Devel Ther. 2011;5:125–46.
Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week randomized double-blind placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(1):60–70.
Findling RL, Kline K, Mckenna K, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia: a 6-week double-blind randomized placebo-controlled trial. Presented at the 55th annual meeting of the American Academy of Child and Adolescent Psychiatry, Chicago (2008).
Maloney AE, Sikich L. Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatr Dis Treat. 2010;6:749–66.
Ely Lilly and Company Ziprexa (olanzapine) Highlights of prescribing information, Indianapolis (2011).
Kuehn BM. FDA panel OKs 3 antipsychotic drugs for pediatric use cautions against overuse. JAMA. 2009;302(8):833–4.
Mozes T, Ebert T, Ebert SE, et al. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2006;16:393–403.
Jensen JB, Kumra S, Leitten W, et al. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol. 2008;18(4):317–26.
Sikich L, Hamer R, Bashford R, et al. A pilot study of risperidone olanzapine and haloperidol in psychotic youth: a double-blind randomized 8-week trial. Neuropsychopharmacology. 2004;29:133–45.
Sikich L, Frazie JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165(11):1420–31.
DelBello MP, Findling RL, Wang PP, et al. Efficacy and safety of ziprasidone in pediatric bipolar disorder. Presented at the 63rd annual meeting of the Society of Biological Psychiatry, Washington DC (2008).
Roessner V, Plessen KI, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders part II: pharmacological treatment. The ESSTS Guidelines Group Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002;41:921–7.
McDougle CJ, Stigler KA, Erickson CA, et al. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008;69(4):15–20.
Elbe D, Carandang CG. Focus on ziprasidone: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2008;17(4):220–9.
Clinical Trialsgov Safety and tolerability of ziprasidone in adolescents with schizophrenia ClinicalTrialsgov identifier: NCT00265382.
Findling RL, Robb A, Nyilas M, et al. Multiple-center randomized double-blind placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432–41.
Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533–40.
Findling RL, McNamara NK, Youngstrom EA, et al. An open-label study of aripiprazole in children with a bipolar disorder. J Child Adolesc Psychopharmacol. 2011;21(4):345–51.
Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21(8):600–20.
Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011;21(8):621–45.
Curran MP. Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients. Paediatr Drugs. 2011;13(3):197–204.
Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715–36.
Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol. 2011;7(7):829–46.
Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders an open-label dose-escalation study. J Clin Psychopharmacol. 2008;28(4):441–6.
Findling RL, Kauffman R, Sallee FR, et al. An open-label study of aripiprazole: pharmacokinetics tolerability and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol. 2009;19(4):431–9.
Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, et al. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit. 2008;30(4):462–6.
Crocq MA, Guillon MS, Bailey PE, et al. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. Eur Psychiatry. 2007;22:453–4.
Findling RL, Mcnamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry. 2004;65(6):30–44.
Jensen PS, Buitelaar J, Pandina GJ, et al. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adoles Psychiatry. 2007;6(2):104–20.
McCormack PL. Olanzapine: in adolescents with schizophrenia or bipolar I disorder CNS. Drugs. 2010;24(5):443–52.
Findling RL, Johnson JL, McClellan J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry. 2010;49(6):583–94.
Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol. 2000;20(2):220–5.
Lobo ED, Robertson-Plouch C, Quinlan T, et al. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model. Paediatr Drugs. 2010;12(3):201–11.
Alfaro CL, Wudarsky M, Nicolson R, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol clozapine or olanzapine. J Child Adolesc Psychopharmacol. 2002;12(2):83–91.
Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177–93.
Findling R. Use of quetiapine in children and adolescents. J Clin Psychiatry. 2003;63:27–31.
Findling RL, Reed MD, O’Riordan MA, et al. Effectiveness safety and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):792–800.
Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry. 2009;18:418–28.
DelBello MP, Chang K, Welge JA, et al. A double-blind placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11(5):483–93.
McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics tolerability and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry. 2000;61:252–60.
Winter HR, Earley WR, Hamer-Maansson JE, et al. Steady-state pharmacokinetic safety and tolerability profiles of quetiapine norquetiapine and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol. 2008;18(1):81–98.
Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509–22.
Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):199–204.
Seroquel XR (quetiapine fumarate) tablets. Prescribing information. Astra Zeneca Pharmaceutical Wilmington Delaware (2011).
Castro-Fornieles J, Parellada M, Soutullo CA, et al. Antipsychotic treatment in, child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol. 2008;18(4):327–36.
Fleischhaker C, Heiser P, Hennighausen K, et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine olanzapine and risperidone. J Neural Transm. 2008;115(11):1599–608.
Lemmon ME, Gregas M, Jeste SS. Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population. J Child Neurol. 2011;26(4):428–32.
Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17(5):647–56.
Bishop JR, Pavuluri MN. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatr Dis Treat. 2008;4(1):55–68.
Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61(4):545–50.
Calarge CA, Ellingrod VL, Acion L, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009;19(5):373–82.
Aman MG, Vinks A, Remmerie B, et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther. 2007;29(7):1476–86.
Thyssen A, Vermeulen A, Fuseau E, et al. Population pharmacokinetics of oral risperidone in children adolescents and adults with psychiatric disorders. Clin Pharmacokinet. 2010;49(7):465–78.
Klampfl K, Taurines R, Preuss A, et al. Serum concentrations therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry. 2010;43(2):58–65.
Open-Label study to evaluate the safety and pharmacokinetics of single- and multiple-dose extended-release OROS paliperidone in pediatric subjects (≥10 to ≤17 years of age) with schizophrenia schizoaffective disorder or schizophreniform disorder. Johnson & Johnson Pharmaceutical Research & Development LLCER OROS Paliperidone: Clinical Study Report Synopsis PALIOROS-PSZ-1001 (Accessed January 2012).
Vermeir M, Naessens I, Remmerie B, et al. Absorption metabolism and excretion of paliperidone a new monoaminergic antagonist in humans. Drug Metab Dispos. 2008;36(4):769–79.
® (paliperidone) extended-release tablets: prescribing information. Titusville: Ortho-McNeil Janssen Pharmaceuticals (2009).
Marino J, Caballero J. Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy. 2008;28(10):1283–98.
Delbello MP, Versavel M, Ice K, et al. Tolerability of oral ziprasidone in children and adolescents with bipolar mania schizophrenia or schizoaffective disorder. Child Adolesc Psychopharmacol. 2008;18(5):491–9.
Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39:292–9.
Stigler KA, Potenza MN, Posey DJ, et al. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence clinical relevance and management. Paediatr Drugs. 2004;6(1):33–44.
Blair J, Scahill L, State M, et al. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry. 2005;44:73–9.
Scahill L, Blair J, Leckman JF, et al. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. J Psychopharmacol. 2005;19(2):205–6.
Sallee FR, Miceli JJ, Tensfeldt T, et al. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:720–8.
Lincoln J, Stewart ME, Preskorn SH. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone. J Psychiatr Pract. 2010;16(2):103–14.
Miceli JJ, Wilner KD, Hansen RA, et al. Single and multiple dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):S5–13.
Prakash C, Kamel A, Cui D, et al. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49(suppl 1):S35–42.
Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab. 2007;8(6):612–22.
Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9–20.
Clozaril (clozapine): prescribing information. East Hanover: Novartis pharmaceutical Co (2011).
Jaquenoud Sirot E, Knezevic B, Morena GP, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009;29(4):319–26.
Frazier JA, Cohen LG, Jacobsen L, et al. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol. 2003;23(1):87–91.
Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit. 2006;28(6):744–9.
Aripiprazole/Abilify: prescribing information. Bristol: Otsuka Pharmaceutical America Inc (2009).
Hendset M, Hermann M, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol. 2007;63(12):1147–51.
Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole a new antipsychotic following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet. 2007;22(5):358–66.
Sparshatt A, Taylor D, Patel MX, et al. Systematic review of aripiprazole—dose plasma concentration receptor occupancy and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71(11):1447–56.
Risperdal (risperidone): prescribing information. Titusville: Ortho-McNeil-Janssen Pharmaceuticals Inc (2010).
Aichhorn W, Marksteiner J, Walch T, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol. 2007;17(5):665–74.
Calarge CA, del Miller D. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(2):163–9.
Pichini S, Papaseit E, Joya X, et al. Pharmacokinetics and therapeutic drug monitoring of psychotropic drug in pediatrics. Ther Drug Monit. 2009;31(3):283–318.
Baumann P, Hiemke C, Ulrich S, et al. Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit. 2004;26(2):167–70.
Invega (paliperidone). Extended-release tablets [package insert]. Titusville: Ortho-McNeil-Janssen Pharmaceutical Products (2010).
Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162(5):1010–2.
Troost PW, Lahuis BE, Hermans MH, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol. 2007;27(1):52–7.
Gerlach M, Hünnerkopf R, Rothenhöfer S, et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry. 2007;40(2):72–6.
Theisen FM, Haberhausen M, Schulz E, et al. Serum levels of olanzapine and its
-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose diagnosis age sex smoking and comedication. Ther Drug Monit. 2006;28(6):750–9.
Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000;38(5):93–414.
Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M, et al. Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit. 2008;30(1):108–12.
Melkersson KI, Scordo MG, Gunes A, et al. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry. 2007;68:697–704.
Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007;46(5):359–88.
Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose cigarette smoking age sex and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24(1):70–8.
Chermá MD, Reis M, Hägg S, et al. Therapeutic drug monitoring of ziprasidone in a clinical treatment setting. Ther Drug Monit. 2008;30(6):682–8.
Ozdemir V, Kalow W, Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C>A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 2001;21:603–7.
Eap CB, Bender S, Jaquenoud Sirot E, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004;24:214–9.
Thombre AG, Herbig SM, Alderman JA. Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Pharm Res. 2011;28(12):3159–70.
Geodon (ziprasidone) : US prescribing information. New York: Pfizer Inc 2010.
Labellarte MJ, Crosson JE, Riddle MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2003;42(6):642–50.
Correll CU, Lops JD, Figen V, et al. QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry. 2011;72(6):854–60.
PubMed CrossRef Copyright information
© Springer International Publishing Switzerland 2013